Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell-specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1-deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 can be expressed on some myeloid cells as well, and changes in the myeloid compartment could lead to an influx of inflammatory cells into various, distant tissues/organs and inciting organ damage”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Strauss et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“However, similar to its role in infections, PD-1 expression inversely correlates with M1 polarization and phagocytic potency of tumor-associated M (TAM) against tumor (7, 8).”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 2×
“Myeloid-specific PD-1 ablation induces improved T cell functionality Previously, it was determined that monocyte/macrophage terminal differentiation is controlled by the combined actions of retinoid receptors and the nuclear receptor peroxisome proliferator–activated receptor (PPAR), which is regulated by cholester…”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Cited by
Items 201–300 of 459
Long-term exposure to house dust mites accelerates lung cancer development in mice
Wang, D., Li, W., Albasha, N., Griffin, L., Chang, H., Amaya, L., Ganguly, S., Zeng, L., Keum, B., González-Navajas, J. M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02587-9 · Cited by 25
Yeo, A. T., Shah, R., Aliazis, K., Pal, R., Xu, T., Zhang, P., Rawal, S., Rose, C. M., Varn, F. S., Appleman, V. A., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0655 · Cited by 25
“In addition, PD-1 regulates differentiation, fate commitment, and output of myeloid cells from the bone marrow during emergency myelopoiesis (19).”
Self-citationNK cell based immunotherapy against oral squamous cell carcinoma
Zhang, Y., Xie, J., Wu, H., Huang, J., Zheng, D., Wang, S., Jia, X., He, Z., Gong, Y., Ju, L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440764 · Cited by 27
“Enhancing NK cell function might involve disrupting their immunosuppressive interactions within the tumor microenvironment (TME), particularly with PD-1-expressing myeloid-derived suppressor cells (MDSCs), although direct interactions between these cells have not yet been documented (138).”
BackgroundRudd, C. E. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz8128 · Cited by 24
The role of myeloid-derived suppressor cells in hematologic malignancies
Gunes, E. G., Rosen, S. T., & Querfeld, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000662 · Cited by 24
Farag, K., Makkouk, A., & Norian, L. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668494 · Cited by 24
“Finally, because PD-1 is expressed on myeloid cells, the use of anti-PD-1 may relieve immune suppression originating from this cell lineage (77).”
BackgroundReprogramming the lipid metabolism of dendritic cells in tumor immunomodulation and immunotherapy
Sun, Z., Zhang, L., & Liu, L. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115574 · Cited by 23
The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia
Arrieta, V. A., Najem, H., Petrosyan, E., Lee-Chang, C., Chen, P., Sonabend, A. M., & Heimberger, A. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413382 · Cited by 23
“Recently, it was shown that cancer-driven emergency myelopoiesis, an increase in myeloid cells derived from cancer-related inflammation, leads to an increase in MDSCs in the periphery [38].”
BackgroundMacrophage-mediated anti-tumor immunity against high-risk neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2022) · Genes and Immunity · doi:10.1038/s41435-022-00172-w · Cited by 24
Jin, Y., Yu, G., Hu, P., Yang, C., Li, X., Chen, X., Wei, Q., & Wang, J. (2020) · Immunologic Research · doi:10.1007/s12026-020-09155-3 · Cited by 23
“In mice, myeloid-specific PD-1 ablation induced more potent antitumor immunity than T cell–specific PD-1 ablation [11].”
BackgroundInfluentialUnlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
Desimpel, P.-H., Petit, P.-F., den Eynde, B. J. V., & Zhu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708873 · Cited by 23
Sri-ngern-ngam, K., Keawvilai, P., Pisitkun, T., & Palaga, T. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101369 · Cited by 22
“Several studies showed that PD-1 expression is involved in suppressing innate inflammatory responses to sepsis [29] and myeloid cell-specific PD-1 deletion induced increased T effector memory cells with improved functionality, and mediated anti-tumor protection [30].”
BackgroundMabrouk, A. A., El-Mezayen, N. S., Awaad, A. K., Tadros, M. I., El-Gazayerly, O. N., & El-Refaie, W. M. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104228 · Cited by 22
Plasma membrane receptors of tissue macrophages: functions and role in pathology
Gordon, S., Plüddemann, A., & Mukhopadhyay, S. (2020) · The Journal of Pathology · doi:10.1002/path.5404 · Cited by 26
“PD-1 expression by TAMs has been shown to inhibit phagocytosis and tumour immunity, whereas another recent study reported that targeted deletion of PD-1 in myeloid cells induces antitumor immunity [99,132].”
BackgroundConnections between Metabolism and Epigenetic Modification in MDSCs
Dai, H., Xu, H., Wang, S., & Ma, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197356 · Cited by 23
“In a hypoxic environment, MDSCs inhibit T cell metabolism by hoarding key amino acids [55].”
BackgroundAlternative Checkpoints as Targets for Immunotherapy
Pant, A., Medikonda, R. T., & Lim, M. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00983-y · Cited by 25
Guth, A., Monk, E. M., Agarwal, R., Bergman, B. C., Berry, K. A. Z., Minic, A. D., Jordan, K. R., & Schlaepfer, I. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249660 · Cited by 22
“The possibility that checkpoint inhibitors also play a role in other immune cells like myeloid cells remains to be explored [43].”
BackgroundCarnevalli, L. S., Taylor, M. A., King, M. A., Coenen-Stass, A. M. L., Hughes, A. M., Bell, S., Proia, T. A., Wang, Y., Ramos‐Montoya, A., Wali, N., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0961 · Cited by 23
Tritz, Z. P., Ayasoufi, K., & Johnson, A. J. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab066 · Cited by 24
Targeting SHP1 and SHP2 to suppress tumors and enhance immunosurveillance
Zhao, Y., & Jiang, L. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.008 · Cited by 22
Eissa, I. R., Mukoyama, N., Abdelmoneim, M., Naoe, Y., Matsumura, S., Bustos‐Villalobos, I., Ichinose, T., Miyajima, N., Morimoto, D., Tanaka, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33550 · Cited by 21
“onstrated that PD-1 deficiency in myeloid cells was crucial for the antitumor response and suppressed tumor growth.(51) CD8 T cells are activated more strongly by PD-1-deficient DCs than by DCs expressing PD-1.”
BackgroundTNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
Ridder, K. D., Locy, H., Piccioni, E., Zuazo, M., Awad, R. M., Verhulst, S., Bulck, M. V., Vlaeminck, Y. D., Lecocq, Q., Reijmen, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.811867 · Cited by 21
“In accordance with recent reports on the negative impact of PD-1 myeloid cells on T-cell amplification responses (31, 32), PD-1 positivity was also evaluated, showing a similar five-fold increase for PD-1 and PD-L1 within the tumor-infiltrated CD11b fraction upon LLCFluc progression (Figure 2B).”
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
Schöniger, S., & Jasani, B. (2022) · Animals · doi:10.3390/ani12192661 · Cited by 24
“Mice with myeloid-specific ablation of PD-1 lacked GMPs and MDSCs, had increased numbers of systemic effector myeloid cells and T effector memory cells, and showed inhibition of tumor growth [19].”
BackgroundInfluentialGaißler, A., Bochem, J., Spreuer, J., Ottmann, S., Martens, A., Amaral, T. M. S., Wagner, N. B., Claassen, M., Meier, F. E., Terheyden, P. A. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006802 · Cited by 22
PD-1 endocytosis unleashes the cytolytic potential of checkpoint blockade in tumor immunity
Saad, E. B., Oroya, A., Anto, N. P., Bachais, M., & Rudd, C. E. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114907 · Cited by 24
Zhang, Z., Liu, L., Ma, C., Cui, X., Lam, R. H. W., & Chen, W. (2021) · Small Methods · doi:10.1002/smtd.202100197 · Cited by 21
Jiang, H., Pang, J., Li, T., Akofala, A., Zhou, X., Yi, C., Ning, S., Gao, X., Qiao, Y., & Kou, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06469-4 · Cited by 20
“Compared to T cell-specific PD-1 knockout, conditional deletion of PD-1 in myeloid cells significantly suppresses tumor growth [25].”
Coronary atherosclerosis and chemotherapy: From bench to bedside
Zhou, F., Zhu, X., Liu, Y. Z., Sun, Y., Zhang, Y., Cheng, D., & Wang, W. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1118002 · Cited by 21
Circadian rhythms of macrophages are altered by the acidic tumor microenvironment
Knudsen-Clark, A. M., Mwangi, D., Cazarin, J., Morris, K. M., Baker, C. D., Hablitz, L. M., McCall, M. N., Kim, M., & Altman, B. J. (2024) · EMBO Reports · doi:10.1038/s44319-024-00288-2 · Cited by 20
“Circadian regulation of macrophages is of particular interest given recent evidence of 24-h circadian variation in the frequency of TAMs expressing surface markers associated with pro-or anti-tumorigenic phenotypes (Aiello et al, 2020; Strauss et al, 2020; Tsuruta et al, 2022).”
Gill, G. S., Kharb, S., Goyal, G., Das, P., Kurdia, K. C., Dhar, R., & Karmakar, S. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2504906 · Cited by 24
Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment
Xiong, J., Wang, H., & Wang, Q. (2021) · Advanced Biology · doi:10.1002/adbi.201900311 · Cited by 21
Self-citationTardos, E. C., Baglioni, M. V., & Bekiaris, V. (2021) · Cancers · doi:10.3390/cancers13184647 · Cited by 20
“However, recent data suggest a critical role of the ICR PD-1 (programmed death-1) in myeloid cells [10,11], while evidence from mouse and human studies supports a potential important role for different ICRs in innate-like T cell subsets.”
BackgroundLim, J. X., Lai, C., Mallett, G., McDonald, D., Hulme, G., Laba, S., Shapanis, A. G., Payne, M., Patterson, W., Alexander, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216587120 · Cited by 19
“Recent reports have shown that PD-1 blockade can enhance antitumor immunity by specifically targeting the innate immune cells such as macrophages in the TME (39).”
Yang, Y., Meng, W., & Wang, Z. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2804069 · Cited by 20
“[26] found that PD-1 in myeloid cells might be more immunosuppressive effect than PD-1 in T cells, and myeloid cells may play a leading role in tumor immune escape.”
BackgroundChan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J. W., Witteles, R. M., Nguyen, P. K. P., Cheng, P. P., & Zhu, H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01024-0 · Cited by 20
“Beyond the role of PD-1/PDL-1 in T cell exhaustion, a PD1-deficient mouse model with selective targeting of myeloid cells suggested that this pathway also acts as an important negative regulator of cholesterol synthesis and uptake [68].”
BackgroundTargeting the spectrum of immune checkpoints in prostate cancer
Sena, L. A., Denmeade, S. R., & Antonarakis, E. S. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1949287 · Cited by 20
Multimodal predictors for precision immunotherapy
Roelofsen, L. M., Kaptein, P., & Thommen, D. S. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100071 · Cited by 20
“In addition, recent data from murine models suggest that PD-1 blockade may exert a major effect via myeloid cells, as based on experiments where PD-1 expression is selectively absent on these cells.(69) To date, however, it is not clear whether this observation can be translated to patients and whether the presence of…”
BackgroundXu, P., Zhang, X., Chen, K., Zhu, M., Jia, R., Zhou, Q., Yang, J., Dai, J., Jin, Y., & Shi, K. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0595 · Cited by 20
Cancer-Related Immune Therapies
Miteva, K., Anker, M. S., Fechner, H., Lehmann, L., & Linthout, S. V. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.06.008 · Cited by 18
Pro- vs. Anti-Inflammatory Features of Monocyte Subsets in Glioma Patients
Lehman, N., Kowalska, W., Zarobkiewicz, M. K., Mazurek, M., Mrozowska, K., Bojarska-Junak, A. A., & Rola, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031879 · Cited by 19
“This suggests that the PD-1/PD-L1 pathway suppresses antitumor immunity not only by suppressing signalling in T cells but also by inhibiting antigen presentation by monocytes [35,36].”
BackgroundCell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 22
Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
Khononov, I., Jacob, E., Fremder, E., Dahan, N., Harel, M., Raviv, Z., Krastev, B. M., & Shaked, Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001996 · Cited by 20
“30 32 Thus, it is possible that anti-PD1 treatment affects PD1-expressing ‘on-target’ CTLs or other ‘off-target’ immune cell types, in a manner that ultimately contributes to tumor aggressiveness.”
BackgroundSilva, S. B., Wanderley, C. W. S., & Colli, L. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826577 · Cited by 19
“Therefore, this could help to polarize immune responses towards a suppressive spectrum, as exemplified by the PD-L1 persistent inducement of FOXP3 expression (FOXP3 ) in PD-1+ T-cells (57), which are characteristically associated with a decreased capacity to reinvigorate into anti-tumoral responses despite ICIs’ activ…”
BackgroundAponte-López, A., Enciso, J., Muñoz-Cruz, S., & Fuentes‐Pananá, E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155293 · Cited by 17
“Although PD-1 has not been studied in MCs, PDCD1 deletion in myeloid cells induces antitumor immunity in a mouse model of cancer [65].”
BackgroundHuman splenic myeloid derived suppressor cells: Phenotypic and clustering analysis
Cole, K., Ly, Q. P., Hollingsworth, M. A., Cox, J. L., Padussis, J. C., Foster, J. M., Vargas, L. M., & Talmadge, J. E. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104317 · Cited by 17
Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
Bleve, A., Consonni, F. M., Porta, C., Garlatti, V., & Sica, A. (2022) · Cancers · doi:10.3390/cancers14030510 · Cited by 21
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Cimadamore, A., Massari, F., Santoni, M., López-Beltrán, A., Cheng, L., Scarpelli, M., Montironi, R., & Moch, H. (2020) · Current Drug Targets · doi:10.2174/1389450121666200324151056 · Cited by 17
Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways
Knutson, K. L. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300674 · Cited by 17
The Role of Programmed Death-1 in Type 1 Diabetes
Tucker, C., Dwyer, A. J., Fife, B. T., & Martinov, T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01384-6 · Cited by 17
“ry monocyte infiltration and increased antigen presentation due to altered cholesterol metabolism [73].”
BackgroundDenis, M., Mathé, D., Micoud, M., Choffour, P., Grasselly, C., Matera, E., & Dumontet, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011943 · Cited by 17
“A recent publication showed that the presence or absence of B cells had no impact on the efficacy of anti-PD-1 (27).”
BackgroundResultGarcía-Vicente, L., Martínez-Fernández, M., Borja, M., Tran, V., Álvarez-Vázquez, A., Flores-Hernández, R., Ding, Y., González-Sánchez, R., Granados, A. A., McGeever, A., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08092-x · Cited by 17
“Checkpoint ligands were expressed by tumor cells and immune cells, accordingly with recent studies that show the expression of checkpoint molecules by myeloid cells 49,65 .”
Sun, Q., Xiao, L., Cui, Z., Yang, Y., Ma, J., Huang, Z. D., Zhang, J., & Chen, J. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00638-z · Cited by 16
“Meanwhile, PD-1 blockers also led to the inhibition of MDSCs expansion and function, which is consistent with previous studies [39, 40].”
ResultResearch progress on the role of cholesterol in hepatocellular carcinoma
Li, P., Yan, Q., Chen, Z., Hu, Y., Sun, Y., Yu, M., Wu, Y., Yao, Y., Tao, L., Chen, F., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175410 · Cited by 16
New insights into the interaction of the immune system with non-small cell lung carcinomas
Hofman, P. M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-178 · Cited by 16
“Recently the expression of checkpoint molecules on neutrophils and MDSCs was demonstrated by different studies and interest was shown using mice models in inducing targeted deletion of PD-1 or of PD-L1 in myeloid cells to bring about an anti-tumor immune reaction (52,53).”
BackgroundZhang, Z., Zhou, H., Liu, Y., Ren, J. L., Wang, J., Sang, Q., Lan, Y., Wu, Y., Yuan, H., Ni, W., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108173 · Cited by 15
Edmunds, G. L., Wong, C. C. W., Ambler, R., Milodowski, E., Alamir, H., Cross, S., Galea, G., Wülfing, C., & Morgan, D. J. (2022) · Communications Biology · doi:10.1038/s42003-021-02972-8 · Cited by 15
Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
Pandey, P., Khan, F., Upadhyay, T. K., & Maqsood, R. (2023) · Molecules · doi:10.3390/molecules28020862 · Cited by 16
“The effect of PD-1 on the metabolism of myeloid cells is yet unknown, however targeting PD-1 that is unique to myeloid cells inhibits tumor growth more effectively than targeting PD-1 that is exclusive to T cells [56,57].”
BackgroundInnate myeloid cells in the tumor microenvironment
Duhan, V., & Smyth, M. J. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.01.001 · Cited by 15
Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions
Fathi, M., Razavi, S., Sojoodi, M., Ahmadi, A., Ebrahimi, F., Namdar, A., Hojjat‐Farsangi, M., Gholamin, S., & Jadidi‐Niaragh, F. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2160703 · Cited by 15
Rational therapeutic targeting of myeloid cells in glioblastoma: challenges and perspectives
Akay, F., & Saleh, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1472710 · Cited by 14
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
Kuah, C. Y., Monfries, R., Quartagno, M., Seckl, M. J., & Ghorani, E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231210271 · Cited by 14
“23 Finally, CD4 regulatory T cells expressing the transcription factor FOXP3 (Tregs) play an important physiological role in negatively regulating T-cell responses, tumours are often enriched with activated Treg populations and depleting them can result in anti-cancer effects.”
Green, C., Chacon, J. A., Godinich, B. M., Hock, R. A., Kiesewetter, M., Raynor, M., Marwaha, K., Maharaj, S. S., & Holland, N. A. (2023) · Cancers · doi:10.3390/cancers15245707 · Cited by 14
“…becomes especially relevant when observing the effects of PD-1 deficiency leading to significantly increased cellular levels, creating the perfect environment for prevention through statins as a two-edged sword in regulating patient lipid levels and preventing atherosclerosis advancement [23,26].”
BackgroundPD-L1 restrains PD-1+Nrp1lo Treg cells to suppress inflammation-driven colorectal tumorigenesis
Poschel, D. B., Klement, J. D., Merting, A. D., Lu, C., Zhao, Y., Yang, D., Xiao, W. L., Zhu, H., Rajeshwari, P., Toscano, M. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114819 · Cited by 16
Alarm Functions of PD-1+ Brain-Resident Memory T Cells
Musial, S. C., Kleist, S. A., Degefu, H. N., Ford, M. A., Chen, T., Isaacs, J. F., Boussiotis, V. A., Skorput, A. G. J., & Rosato, P. C. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400295 · Cited by 11
Self-citationMalode, A., Makwana, B., Patel, V., Khadke, S., Parikh, A., Bagga, A., Dani, S. S., & Ganatra, S. (2025) · Anaesthesia · doi:10.1111/anae.16493 · Cited by 15
“Evaluations generally focus on assessing patients ’ ability to handle hypotension and haemodynamic stability [4].”
Lipid Metabolism and Immune Checkpoints
Liao, Q., Zhou, Y., Xia, L., & Cao, D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_12 · Cited by 15
Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
Hare, L., Burke, G. A. A., & Turner, S. D. (2021) · Cancers · doi:10.3390/cancers13236003 · Cited by 14
“This interacts with the programmed cell death 1 (PD-1) receptor to dampen the T cell immune response against the tumour, although the precise mechanism via which this occurs is currently under investigation [71,72].”
BackgroundNoncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
Long, Y., Yu, X., Chen, R., Tong, Y., & Gong, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910704 · Cited by 16
“Myeloid-PD-1 altered the balance of differentiation into monocyte and granulocyte cells (106).”
BackgroundConcomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses
Ventura, P., Gakovic, M., Fischer, B. A., Spinelli, L., Rota, G., Pathak, S., Khameneh, H. J., Zenobi, A., Thomson, S., Birchmeier, W., et al. (2022) · EMBO Reports · doi:10.15252/embr.202255399 · Cited by 14
“…a recent report demonstrated that myeloid-specific PD-1 deletion decreased tumor growth more efficiently than T cell-specific PD-1 deletion (Strauss et al , 2020), suggesting that the effects of PD-1 blockade are not solely mediated by T cells but also by other cells present in the tumor…”
Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma
Zhou, S., Sun, H., Choi, S. Y., & Yin, J. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2809206 · Cited by 15
“genitor cells revealed more potent antitumor activity and tumor growth suppression [118].”
Wright, Q., Cruz, J. L. G., Wells, J. W., & Leggatt, G. R. (2021) · Cancers · doi:10.3390/cancers13133310 · Cited by 15
“Other preclinical studies using myeloidspecific deletion of PD-1 have shown a role for PD-1 on myeloid cells, in inhibiting antitumor immunity [51].”
BackgroundGiovannini, C., Suzzi, F., Tovoli, F., Bruccoleri, M., Marseglia, M., Alimenti, E., Fornari, F., Iavarone, M. A., Piscaglia, F., & Gramantieri, L. (2023) · Cancers · doi:10.3390/cancers15061661 · Cited by 14
“In this study, myeloid cell-specific PD1 ablation was more effective than T-cell-specific PD1 ablation in decreasing tumor growth [12].”
BackgroundResultInfluentialXu, T., Dai, J., Tang, L., Sun, L., Si, L., & Guo, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03502-7 · Cited by 13
“During cancer development and progression, HSCs reenter the cell cycle and differentiate into common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs); however, HSPCs gradually lose their full differentiation capacity under the pressure of chronic low-level activation signals from cancer cells, re…”
BackgroundKRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04619-0 · Cited by 13
Hematologic malignancies following immune checkpoint inhibition for solid tumors
van Eijs, M. J. M., van der Wagen, L. E., Mous, R., Leguit, R. J., van de Corput, L., van Lindert, A. S. R., Suelmann, B. B. M., Kamphuis, A. M., Nierkens, S., & Suijkerbuijk, K. P. M. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03230-4 · Cited by 13
“However, regarding myeloid lineage, myeloid-specific PD-1 ablation in a murine melanoma model enhanced effector T response and led to a larger decrease in tumor growth than T-cell-specific PD-1 ablation [12].”
Turker, I., & Johnson, D. B. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2254218 · Cited by 14
“Therefore, blocking PD-1 and its ligands may also result in decreased tumor growth, independent of T-cell activation, by increased tumorinfiltrating macrophage activity [24,25] (Figure 1).”
BackgroundImmune Checkpoint Inhibitor-Induced Liver Injury
Gudd, C. L. C., Sheth, R., Thursz, M. R., Triantafyllou, E., & Possamai, L. A. (2023) · Seminars in Liver Disease · doi:10.1055/s-0043-1776761 · Cited by 12
Myeloid Cell‐Triggered In Situ Cell Engineering for Robust Vaccine‐Based Cancer Treatment
Li, W., Su, J., Zhang, B., Zhao, L., Zhuo, S., Wang, T., Hu, H., & Li, Y. (2024) · Advanced Materials · doi:10.1002/adma.202308155 · Cited by 12
Choi, J. H., Pant, A., Medikonda, R. T., Kim, Y., Routkevitch, D., Saleh, L., Tong, L., Chan, H. Y., Nedrow, J. R., Jackson, C. M., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1940673 · Cited by 12
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
Marx, S., Wilken, F., Miebach, L., Ispirjan, M., Kinnen, F., Paúl, S., Bien-Möller, S., Freund, E., Baldauf, J., Fleck, S. K., et al. (2022) · Cancers · doi:10.3390/cancers14235751 · Cited by 11
“In addition, myeloid cell-specific PD1 ablation increased Tem cells and improved their functionality, ultimately mediating anti-tumor immunity despite a perceived PD1 expression on T cells [45].”
BackgroundLim, S., Park, J.-H., & Chang, H. K. (2022) · Korean journal of urology · doi:10.4111/icu.20220031 · Cited by 11
“Furthermore, myeloid cell-specific PD-1 ablation leads to enhanced T-effector memory cells with anti-tumor immunity, suggesting that the PD-1 antibody directly affects the functionality of myeloid cells, including DC [31].”
Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies
Rounis, K., Makrakis, D., Gioulbasanis, I., Ekman, S., Petris, L. D., Mavroudis, D., & Agelaki, S. (2022) · Life · doi:10.3390/life12060880 · Cited by 12
“Interestingly, in a mouse model with conditional targeting of the Pdcd1 gene, specific PD-1 ablation in myeloid cells had a more pronounced effect on boosting antitumor immunity and restricting tumor growth and progression compared to specific PD1 ablation on T cells [83].”
BackgroundLu, H., Xu, Z., Shao, L., Li, P., & Xia, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37092 · Cited by 10
“In contrast, the pro-tumorigenic M2 type is immunosuppressive and is characterized by a low expression of inhibitory molecules including PD-L1 and Tim3 at late stage of immune response [55,56].”
Foster, C., Du, J., Pundel, O. J., Geer, M. J., Ripert, R. C., Liu, J., Heim, T. A., Araki, K. Y., Lund, A. W., Wang, J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2427254122 · Cited by 10
“However, a more recent report suggests that in mice, PD - 1 action in the myeloid cell compartment is important for its anti - tumor effect against MC38 tumors ( 28 , 29 ).”
TIM3 is a context-dependent coregulator of cytotoxic T cell function
Alamir, H., Wong, C. C. W., Alsubaiti, A., Edmunds, G. L., Alismail, M., Huynh, L., Shi, Y., Lewis, P. A., Grant, T., Alsulaimani, S., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adk4594 · Cited by 10
Signal-Strength and History-Dependent Innate Immune Memory Dynamics in Health and Disease
Geng, S., Pradhan, K., & Li, L. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_485 · Cited by 10
Sheban, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183578 · Cited by 11
“More recent studies confirmed this observation and showed in more detail how the deletion of PD-1 in TAMs induces anti-tumor immunity and suppresses tumor growth (58, 59).”
ResultNFKB2 mediates colorectal cancer cell immune escape and metastasis in a STAT2/PD‐L1‐dependent manner
Zhang, J., Ma, F., Li, Z., Li, Y., Sun, X., Song, M., Yang, F., Wu, E., Wei, X., Wang, Z., et al. (2024) · MedComm · doi:10.1002/mco2.521 · Cited by 10
“45,46 Expanding the range of CRC candidates who could benefit from treatments targeting PD-1/PD-L1 represents an important goal in CRC therapy.”
BackgroundHuman Ferritin Platform and Its Optimized Structures to Enhance Anti‐Cancer Immunity
Lee, B., Lee, H., Huh, J., Yoon, C. J., Oh, S. J., Song, K., Jeong, S., Kim, J., Lee, K., Shin, B. S., et al. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000208 · Cited by 11
Zeng, Y., Huang, J., Pang, J., Pan, S., Wu, Y., Jie, Y., Li, X., & Chong, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1330644 · Cited by 9
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling
Wu, L., Park, S.-H., Jakobsson, H., Shackleton, M. J., & Möller, A. (2024) · Cancers · doi:10.3390/cancers16111950 · Cited by 10
“…endothelial cells (TECs) and myeloid-derived suppressor cells (MDSCs), which are involved in the regulation of immune suppressive signalling [57,58]. endothelial cells (TECs) and myeloid-derived suppressor ), which are involved in the regulation of immune suppressive signalling Understanding…”
BackgroundInfluentialShang, X., Geng, X., Wang, Z., Yuan, S., Ding, S., Liu, G., Ma, X., Sun, X., Wang, H., Sun, Y. H., et al. (2025) · Advanced Science · doi:10.1002/advs.202513182 · Cited by 11
Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer
Mestrallet, G., Brown, M., Vaninov, N., Cho, N. W., Velazquez, L. G., Ananthanarayanan, A., Spitzer, M. H., Vabret, N., Bozkus, C. C., Samstein, R. M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102786 · Cited by 10
“Complementary approaches could also focus on γδ T cells, especially in MMRd cancers with MHCI defects 46 ; DCs 28,47 ; PD-1-and PI3K-γ -expressing myeloid cells 48,49 ; the HLA-E and HLA-G molecules 19,34,50–55 ; WRN inhibitors 56 ; TREM1 myeloid cells 57 ; or vaccination.”
Developmental pathways of myeloid-derived suppressor cells in neoplasia
Abrams, S. I. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104261 · Cited by 9
Ashoori, M. D., Suzuki, K., Tokumaru, Y., Ikuta, N., Tajima, M., Honjo, T., & Ohta, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618711 · Cited by 10
“The significance of PD-1 in monocytes remains unclear, but it may be related to M2-type functions, and their anti-inflammatory nature may contribute to the immunosuppressive tumor microenvironment (29, 40).”
BackgroundPD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
Kondo, R., Kondo, K., Nabeshima, K., Nishikimi, A., Ishida, Y., Shigeoka, T., & Dijkstra, J. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573492 · Cited by 8
“PD-1 is expressed by activated T cells, but also found in other immune cells like B cells and myeloid cells (2, 6, 7).”
A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer
Tarantini, L., Gallucci, G., Inno, A., Camerini, A., Canale, M. L., Larocca, M., Zanelli, F., Pagano, M., Alberti, G., Ciammella, P., et al. (2025) · Cancers · doi:10.3390/cancers17213443 · Cited by 9
Liang, L., Yang, Y., Deng, K., Wu, Y., Li, Y., Bai, L., Wang, Y., & Lu, C. (2024) · Cells · doi:10.3390/cells13131163 · Cited by 9
“Our findings thus determined that IFN β activates PD-1 expression via the pSTAT1-IRF2 pathway in myeloid”
BackgroundInfluentialYakkala, C., Corría-Osorio, J., Kandalaft, L. E., Denys, A. L., Koppolu, B., & Durán, R. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0371 · Cited by 8
Cholesterol: The driving force behind the remodeling of tumor microenvironment in colorectal cancer
Wang, K., Zhang, Y., Si, C., Cao, Y., Shao, P., Zhang, P., Wang, N., Su, G., Qian, J., & Liu, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39425 · Cited by 9
Metadata
- Authors
- Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., & Boussiotis, V. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7183328
- OpenAlex
- W2997277554
- Cited by
- 437
- References
- 73
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 67 · 2023: 83 · 2022: 70 · 2021: 77 · 2020: 59
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA183605, P01CA142106, R01CA212605)
- National Institute of Allergy and Infectious Diseases (R56AI098129)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, myeloid cells, antitumor immunity, myeloid-derived suppressor cells, good manufacturing practices, emergency myelopoiesis, myeloid progenitor cells, cholesterol metabolism, metabolic reprogramming, macrophage differentiation, dendritic cell differentiation, anti-PD-1 therapy, tumor immunology
- MeSH terms
- Animals, Cell Differentiation, Colonic Neoplasms, Female, Male, Melanoma, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.